Panelists discuss the limitations of conventional immunohistochemistry (IHC) in assessing TROP2 expression for targeted therapies in non–small cell lung cancer and highlight how advanced tools such as quantitative continuous scoring (QCS) and normalized membrane ratio (NMR) offer more precise, objective, and functional evaluations of protein expression and internalization, paving the way for improved patient stratification and personalized treatment with antibody-drug conjugates (ADCs).
Panelists discuss the evolving role of advanced biomarker tools like quantitative continuous scoring (QCS) and normalized membrane ratio (NMR) in non–small cell lung cancer (NSCLC), highlighting their potential to overcome limitations of traditional TROP2 assessment, improve prediction of antibody-drug conjugate (ADC) efficacy, and enhance patient selection through more precise and functional tumor profiling.
Sandip P. Patel, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with non–small cell lung cancer.
The panel discusses treatment considerations for consolidation durvalumab.
The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.
The panel looks at a second patient case study.
The panel discusses management of resectable early-stage non–small cell lung cancer.
The panel discusses the factors that go into selecting patients for adjuvant therapy.
The panel discusses reassessing for respectability after certain treatments.
A variety of treatment options in ES NSCLC are explored by key opinion leaders.
The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.
Panelists discuss the utilization of testing and multidisciplinary approaches for testing.
Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.
A panel of experts share unmet needs and clinical practice pearls for community oncologists regarding the treatment of patients with early-stage NSCLC.
Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.
Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.
Ben Levy, MD, reviews the 5-year update and clinical implications of the PACIFIC study which evaluated consolidation immunotherapy in unresectable early-stage NSCLC.
Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.
Sandip Patel, MD, and Ben Levy, MD, discuss the results and clinical implications of the IMPower-010 and KEYNOTE-091 studies of adjuvant immunotherapy in NSCLC.
A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.
Expert perspectives on selecting between neoadjuvant and perioperative chemoimmunotherapy in patients with resectable early-stage NSCLC.
Sandip Patel, MD, reviews the study design, results and clinical implications of the KEYNOTE-671 and NEOTORCH studies that evaluated perioperative chemoimmunotherapy in the treatment of early-stage NSCLC.
David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC
Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.
Ben Levy, MD offers insight into how he approaches the selection of the optimal treatment strategy in early-stage non-small cell lung cancer.
A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.
Sandip P. Patel, MD, discusses optimizing molecular testing for EGFR mutations in lung cancer.
Sandip P. Patel, MD, discusses novel targets in non–small cell lung cancer.
Sandip P. Patel, MD, discusses the utility of consolidative durvalumab in stage III non–small cell lung cancer.
Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.
